Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) shares fell 6.2% during mid-day trading on Monday . The stock traded as low as $4.18 and last traded at $4.21, with a volume of 1,355,039 shares. The stock had previously closed at $4.49.

Several brokerages have issued reports on KERX. Cowen and Company reiterated a “hold” rating on shares of Keryx Biopharmaceuticals in a report on Saturday, April 30th. Morgan Stanley reiterated a “hold” rating on shares of Keryx Biopharmaceuticals in a report on Saturday, April 30th. FBR & Co reiterated a “buy” rating and issued a $13.00 price target on shares of Keryx Biopharmaceuticals in a report on Friday, April 29th. Zacks Investment Research lowered Keryx Biopharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, August 3rd. Finally, Maxim Group lowered Keryx Biopharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, August 1st. Three investment analysts have rated the stock with a sell rating, nine have issued a hold rating and three have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $7.63.

The company’s 50 day moving average price is $6.51 and its 200 day moving average price is $5.20. The firm’s market capitalization is $445.50 million.

Keryx Biopharmaceuticals (NASDAQ:KERX) last posted its earnings results on Monday, August 1st. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by $0.14. The business earned $9.30 million during the quarter, compared to analysts’ expectations of $8.60 million. During the same quarter last year, the business earned ($0.26) EPS. The business’s revenue for the quarter was up 272.0% on a year-over-year basis. On average, analysts anticipate that Keryx Biopharmaceuticals Inc. will post ($1.21) EPS for the current fiscal year.

In other Keryx Biopharmaceuticals news, CFO Scott A. Holmes sold 4,935 shares of the company’s stock in a transaction that occurred on Friday, July 29th. The stock was sold at an average price of $7.36, for a total transaction of $36,321.60. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

A hedge fund recently bought a new stake in Keryx Biopharmaceuticals stock. Royce & Associates LLC bought a new position in Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund bought 341,725 shares of the biopharmaceutical company’s stock, valued at approximately $1,726,000. Royce & Associates LLC owned 0.32% of Keryx Biopharmaceuticals at the end of the most recent quarter.

Keryx Biopharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development of products for the treatment of renal diseases. The Company’s product Auryxia (ferric citrate), also known as Riona in Japan and Fexeric in Europe, is an oral, absorbable iron-based compound, which is indicated for the control of serum phosphorus levels in patients with chronic kidney disease (CKD), on dialysis.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.